Meta-analysis of Dalteparin vs. Apixaban
================

<i>Analysis and visualization developed by [Luis A.
Figueroa](https://twitter.com/LuisFig1706) and [Oscar J.
Ponce](https://twitter.com/PonceOJ)</i>

<h2>
Overall Forestplot
</h2>
<details>
<summary>
<b>Figure 1 -</b> Odds of developing <b>Major Bleeding</b>, <b>Non-Major
Bleeding</b> and <b>Recurrence of Venous Thromboembolism (VTE)</b>
events in the Dalteparin group vs. the Apixaban group
</summary>

<br>

![](8%20Output%20Figures/overall_graph_REML-1.svg)<!-- -->

</details>
<br>
<h2>
Individual Forestplots
</h2>
<details>
<summary>
<b>Figure 2 -</b> Major bleeding forestplot with PM estimator
</summary>

<br>

![](8%20Output%20Figures/major_bleeding_graphs_pm-1.svg)<!-- -->

</details>
<details>
<summary>
<b>Figure 3-</b> Major bleeding forestplot with REML estimator
</summary>

<br>

![](8%20Output%20Figures/major_bleeding_graphs_reml-1.svg)<!-- -->

</details>
<details>
<summary>
<b>Figure 4 -</b> Non-Major Bleeding forestplot with PM estimator
</summary>

<br>

![](8%20Output%20Figures/no_major_bleeding_graphs_pm-1.svg)<!-- -->

</details>
<details>
<summary>
<b>Figure 5 -</b> Non-Major Bleeding forestplot with REML estimator
</summary>

<br>

![](8%20Output%20Figures/no_major_bleeding_graphs_reml-1.svg)<!-- -->

</details>
<details>
<summary>
<b>Figure 6 -</b> Recurrence of VTE forestplot with PM estimator
</summary>

<br>

![](8%20Output%20Figures/TE_recurrence_PM-1.svg)<!-- -->

</details>
<details>
<summary>
<b>Figure 7 -</b> Recurrence of VTE forestplot with REML estimator
</summary>

<br>

![](8%20Output%20Figures/TE_recurrence_REML-1.svg)<!-- -->

</details>
